Retatrutide

Retatrutide is a synthetic multi-receptor peptide agonist incorporating non-proteinogenic residues and a fatty acid modification that promotes albumin binding. It is supplied as a lyophilised solid. As with other lipidated long-chain peptides, analytical verification requires a method appropriate to the modification: reversed-phase HPLC purity with a stated gradient, mass-spectrometric identity confirmation and peptide content determination. Purity claims without a stated method are uninformative for this class. All values on this record are transcribed from the supplier specification sheet and batch certificate of analysis.

Retatrutide was developed as a triple agonist at the GIP, GLP-1 and glucagon receptors, extending the dual-agonist approach by adding glucagon receptor activity intended to increase energy expenditure alongside the incretin effects on insulin secretion and appetite. It entered clinical development in the 2020s. It is an investigational compound: it holds no marketing authorisation in any jurisdiction, and its development programme is ongoing at the time of this review.

Published work examines receptor pharmacology across the three targets and the balance of potencies between them, effects on insulin secretion and glucagon-mediated energy expenditure, appetite and gastric emptying effects shared with the incretin class, and body-weight and glycaemic endpoints measured in phase 1 and phase 2 studies. Pharmacokinetic work covers albumin binding and the resulting exposure profile.

Phase 2 randomised, double-blind, placebo-controlled data have been published in peer-reviewed journals with pre-specified endpoints, and the magnitude of the reported body-weight effect at higher study exposures was large and dose-related. Receptor pharmacology of each of the three targets individually is well established from decades of prior work. Pharmacokinetics supporting weekly intervals in the study protocols are documented.

No phase 3 programme has completed, and no regulatory authority has reviewed a full dossier. Phase 2 trials are, by design, sized for dose-finding rather than for outcome or safety conclusions: participant numbers are in the hundreds, follow-up is under a year, and rare adverse events cannot be detected at that scale. Reported increases in heart rate and gastrointestinal adverse events warrant attention and are not fully characterised. Glucagon receptor agonism introduces effects on hepatic glucose output and on other endpoints whose long-term consequences are unknown. Durability after discontinuation has not been established. And, as with every compound in this catalogue, no data establish equivalence between research-grade material and the material used in those trials. Any confident statement about this compound's efficacy or safety profile currently outruns the evidence.

Store the lyophilised solid as stated in the storage conditions on this record, protected from light and moisture, and equilibrate the sealed vial before opening. Lipidated peptides aggregate readily; agitation, repeated freeze-thaw and prolonged solution storage are the principal analytical risks. This section covers laboratory handling of the material as supplied only, and provides no preparation or administration procedure.

Indexed citations with verified PMIDs appear below. See testing methodology for how analytical values are established and sourcing standards for documentation requirements.